Jiangxi Bio's history dates back to 1969, when it was established as the Jiangxi Branch of the Shanghai Institute of Biological Products under the Ministry of Health. Over more than fifty years of development and accumulation, the company has built a profound foundation in biopharmaceutical technology and a robust industrial base. In 2002, it completed its transformation into a limited liability company, and in December 2017, it underwent a shareholding reform. Through the sustained efforts of several generations of research and management teams, it has grown into a national high-tech leader in China's antitoxin and immune serum product sectors. Guided by the national strategy for developing the biopharmaceutical industry, the company has established a nationwide strategic layout comprising "Three Bases and Two Centers," with eight wholly owned subsidiaries, forming a complete bioproducts industry ecosystem. In Jiangxi, it operates a specialized human pharmaceutical production base focused on the R&D and manufacturing of antitoxins and immune serums; in Gansu Province, it has set up a horse‑breeding and equine plasma‑collection facility to ensure a stable supply of core raw materials at the source; in Inner Mongolia, it has constructed a veterinary pharmaceutical production base compliant with GMP standards, effectively filling an important market gap; in Shenzhen, it has established a cutting-edge drug R&D center that integrates industry, academia, research, and clinical practice to drive biotechnological innovation; and in Hainan, it has developed a pharmaceutical R&D technology service platform to efficiently leverage global high‑quality resources. The company adheres to a vertically integrated, full‑chain development model, establishing a closed-loop management system that covers every stage—from raw material procurement and R&D to production and final delivery. Backed by stringent quality‑control standards and a digital monitoring system, it ensures independent control over core raw materials, optimizes production costs, and maintains product quality at an industry‑leading level. Leveraging the synergistic advantages of its comprehensive industrial chain, the company consistently provides safe, efficient, and reliable bioproducts to customers worldwide, demonstrating strong competitive edge and sustainable growth in the international marketplace. The company's core business encompasses bioproduct R&D and manufacturing, laboratory animal breeding and biotechnology promotion services, pharmaceutical testing and inspection, drug R&D, drug safety evaluation, and related technical services. Its flagship product, tetanus antitoxin (immunoglobulin), has received numerous accolades, including the Gold Award at the 7th ASEAN Traditional Medicine Academic Conference and the "Outstanding New Product" title from Jiangxi Province, and has been recognized as a "Jiangxi Boutique Product" and a "Jiangxi Brand." With outstanding production and sales capabilities, its products are exported to more than 30 countries and regions, serving over one billion users globally, while its market influence and brand reputation continue to grow. The company places great emphasis on technological innovation and talent development, operating multiple provincial‑level or higher research platforms, such as the "Provincial Enterprise Technology Center" and the "Jiangxi Provincial Biomedical Immune Antibody Drug R&D Center," as well as the "Jiangxi Postdoctoral Innovation Practice Base," provincial and municipal Hai Zhi Program workstations, and municipal expert workstations. By implementing a talent‑driven corporate strategy, it has attracted a pool of highly qualified managerial, technical, and R&D professionals, while equipping itself with advanced, digital, and intelligent production and R&D facilities, thereby building strong capabilities in scientific innovation and the commercialization of technological achievements. Throughout its development, the company has repeatedly earned prestigious honors, including designation as a "National High‑Tech Enterprise," and awards such as "National Advanced Collective in Quality Control Work," "Jiangxi Specialized, Fine, Distinctive, and Innovative Enterprise," and "Jiangxi Specialized Small Giant Enterprise." At the same time, the company actively fulfills its social responsibilities, receiving accolades like "Outstanding Enterprise of Jiangxi Province," "Provincial Private Science and Technology Enterprise," "Advanced Grassroots Party Organization of the Province," and "Jiangxi Workers' Vanguard Unit." For many consecutive years, it has also been recognized as one of "Jian City's Top Ten Private Science and Technology Enterprises," a "Civilized Unit," and a "Major Taxpayer." Looking ahead, the company will remain committed to its mission of providing high‑quality medicines to people around the world, with the strategic goal of becoming a "Global Serum Hub." It will continue to introduce advanced international technologies, drive process innovation and product upgrades, and accelerate its capital‑market expansion through major project‑driven initiatives. By further enhancing its core competitiveness and international influence, the company aims to make even greater contributions to the high‑quality development of China's biopharmaceutical industry and to safeguarding public health and well‑being.